Cas:12593-60-1 diammonium phosphate sulphate manufacturer & supplier

Chemical Name:diammonium phosphate sulphate

CAS.NO:12593-60-1

Synonyms:diammonium phosphate sulphate

Molecular Formula:H₁₁N₂O₈PS

Molecular Weight:230.13500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:158ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:176.21000

Exact Mass:229.99700

LogP:0.34740

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like diammonium phosphate sulphate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,diammonium phosphate sulphate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,diammonium phosphate sulphate Use and application,diammonium phosphate sulphate technical grade,usp/ep/jp grade.

Related News: But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. diammonium phosphate sulphate manufacturer INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. diammonium phosphate sulphate supplier China considers self-ruled Taiwan to be part of its territory and has long sought to limit its diplomatic relations and recognition at international bodies such as the W.H.O. diammonium phosphate sulphate vendor But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. diammonium phosphate sulphate factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.